All In Biotech

Drug Trial Radar · NCT07907991

The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

The AIRWARD Study: A Phase III, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate the Efficacy and Safety of Verducatib in Participants With COPD

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 10, 2027

Primary completion

Nov 12, 2029

Study completion Dec 10, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 40 years and older who have chronic obstructive pulmonary disease (COPD) with ongoing symptoms. People can join the study if they are at risk of COPD flare-ups (also called acute exacerbations or sudden worsening of COPD symptoms) even though they use their usual inhaled or oral COPD medicines. They must have had at least 2 moderate COPD flare-ups or at least 1 severe COPD flare-up in the past year, including at least 1 while taking their current COPD treatment. People must also have a blood test result showing less than 300 eosinophils (a type of white blood cell) per microliter. The purpose of this study is to find out whether a medicine called verducatib helps people with COPD have fewer flare-ups or sudden worsening of COPD symptoms over up to about 1.5 years, compared with placebo. The study also looks at whether verducatib delays the time until the first flare-up, how well it is tolerated, improves participants' quality of life, and improves their lung function when compared with placebo. In this study, participants are put into 2 groups randomly, which means by chance. One group takes verducatib as tablets and the other group takes placebo tablets. Placebo tablets look like verducatib tablets but do not contain any medicine. Participants take a tablet by mouth once a day for at least 1 year and up to about 1.5 years. All participants continue their regular COPD treatment during the study. Participants are in the study for at least 1 year and up to about 1 year and 8 months. During this time, they have regular visits at the study site and monthly phone calls from the study staff to check on their COPD symptoms and any health problems. Doctors collect information about participants' health, including blood samples. They record how often participants have moderate or severe COPD flare-ups and how long it takes until the first flare-up. They also measure lung function and ask participants to fill in questionnaires about their symptoms and daily life. Participants have to daily report their symptoms and intake of certain medications in an electronic diary at home. The results are compared between the 2 groups to see whether verducatib helps reduce flare-ups and improves symptoms. The doctors also regularly check participants' health and note any unwanted effects.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • VerducatibDrug

    Verducatib

  • Placebo matching verducatibDrug

    Placebo matching verducatib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)Time frame: Up to week 76

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Pulmonary Associates - Deer Valley Office

    Phoenix, Arizona

  • IMAX Clinical Trials

    La Palma, California

  • Clinical Research Specialists LLC - Kissimmee

    Kissimmee, Florida

  • Optimus U Corporation-Miami-69452

    Miami, Florida

  • Cordova Research Institute

    Miami, Florida

  • Bolanos Clinical Research

    Pembroke Pines, Florida

  • Appalachian Clinical Research

    Adairsville, Georgia

  • Covenant Pulmonary Critical Care

    Atlanta, Georgia

  • Christie Clinic in Champaign on University

    Champaign, Illinois

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • UMASS Memorial Medical Center

    Worcester, Massachusetts

  • Midwest Clinical Research Center - St. Louis

    St Louis, Missouri

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • Temple University

    Philadelphia, Pennsylvania

  • Velocity Clinical Research-Union-68888

    Union, South Carolina

  • Clinical Trials Center of Middle Tennessee, LLC

    Franklin, Tennessee

  • Greater Heights & Memorial Pulmonary and Sleep

    Houston, Texas

  • Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico

    Milan, Italy

  • ASST Fatebenefratelli Sacco

    Milan, Italy

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Italy

  • Pol. Universitario Tor Vergata

    Roma, Italy

  • Hospital Sultan Idris Shah Serdang

    Kajang, Malaysia

  • Hospital Raja Perempuan Zainab II

    Kelantan, Malaysia

  • Institut Perubatan Respiratori

    Kuala Lumpur, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.